Pharmacokinetic analysis of vilobelimab, anaphylatoxin C5a and antidrug antibodies in PANAMO: a phase 3 study in critically ill, invasively mechanically ventilated COVID-19 patients
Abstract Background Vilobelimab, a complement 5a (C5a)-specific monoclonal antibody, reduced mortality in critically ill COVID-19 patients in a phase 3 multicentre, randomized, double-blind, placebo-controlled study. As part of the study, vilobelimab concentrations and C5a levels as well as antidrug...
Main Authors: | Endry H. T. Lim, Alexander P. J. Vlaar, Sanne de Bruin, Simon Rückinger, Claus Thielert, Maria Habel, Renfeng Guo, Bruce P. Burnett, James Dickinson, Matthijs C. Brouwer, Niels C. Riedemann, Diederik van de Beek, the PANAMO study group |
---|---|
Format: | Article |
Language: | English |
Published: |
SpringerOpen
2023-06-01
|
Series: | Intensive Care Medicine Experimental |
Subjects: | |
Online Access: | https://doi.org/10.1186/s40635-023-00520-8 |
Similar Items
-
Anti-C5a antibody vilobelimab treatment and the effect on biomarkers of inflammation and coagulation in patients with severe COVID-19: a substudy of the phase 2 PANAMO trial
by: Endry H. T. Lim, et al.
Published: (2022-12-01) -
Physiologically-based pharmacokinetic modeling for single and multiple dosing regimens of ceftriaxone in healthy and chronic kidney disease populations: a tool for model-informed precision dosing
by: Fawaz Alasmari, et al.
Published: (2023-07-01) -
Pheromone biosynthesis activating neuropeptide family in insects: a review
by: Xiaoyi Dou, et al.
Published: (2023-12-01) -
Hick's Pluralism and Rumi's Mathnawi: the Continued Propagation of Misappropriated Lines
by: Abdul Razak al-Aidrus, Mohamed Ajmal
Published: (2011) -
Comparison of Usability Level of E-Commerce Websites: Daraz and Homeshopping
by: Adnan Ali, et al.
Published: (2022-09-01)